New therapeutic approach for giant cell arteritis!

Dear patients

we would like to inform you about current results regarding studies on the topic: giant cell arteritis:

In a current study at GCA patients with giant cell arteritis have the opportunity to be treated with Secukinumab as part of a Phase III trial. The aim of this study is to minimize the dosage of cortisone. Secukinumab is already approved for treating rheumatoid arthritis and is provided by the sponsor at no cost, thus neither the statutory nor private health insurance would incur any expenses.

Please do not hesitate to contact us.

Your practice team